Ktrans and serum VEGF levels and tumor diameters in the combined treatment group were always lower than those in the other two groups at 3, 7, and 14 days (all P < 0.05), suggesting that donafenib can effectively inhibit angiogenesis in residual tumors. Here, VEGFA is linked to neoplasm.